Phase II trial of BAY 43-9006 (sorafenib; NSC-724772) in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma

Trial Profile

Phase II trial of BAY 43-9006 (sorafenib; NSC-724772) in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Jul 2014

At a glance

  • Drugs Sorafenib (Primary) ; Carboplatin; Paclitaxel
  • Indications Uveal melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Dec 2012 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 10 Jul 2012 Actual end date (1 Jan 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top